Skip to main content
Evidence Snapshot

Tyrosine-protein kinase ITK/TSK

CHEMBL2959 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T04:40:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2959
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase ITK/TSK as ChEMBL target CHEMBL2959, mapped to UniProt Q08881. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase ITK/TSK
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2959
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q08881
Tyrosine-protein kinase ITK/TSK
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase ITK/TSK matters

As of 2026-09-13

Tyrosine-protein kinase ITK/TSK is reviewed as Tyrosine-protein kinase ITK/TSK (UniProt Q08881); Tyrosine-protein kinase ITK/TSK shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 15 approved drugs, 3410 compounds, and 539 assays, with lead potency reaching pChEMBL 10.4.

Disease context
chromophobe renal cell carcinoma

Tyrosine-protein kinase ITK/TSK shows approved-linked disease relevance led by chromophobe renal cell carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include PAZOPANIB HYDROCHLORIDE.

Start review with chromophobe renal cell carcinoma because it currently carries approved-linked support. Linked drugs include PAZOPANIB HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 15 approved drugs, 3410 compounds, and 539 assays for this target. The dominant activity type is IC50. CHEMBL5913558 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL5913558 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
15 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase ITK/TSK matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q08881, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why chromophobe renal cell carcinoma is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3410
Total Compounds
539
Total Assays
15
Approved Drugs
IC50: 2471.0, KI: 799.0, EC50: 25.0, KD: 144.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5913558
 10.4 IC50 —
No preferred name
CHEMBL5945729
 10.3 IC50 —
No preferred name
CHEMBL5878223
 10.1 IC50 —
No preferred name
CHEMBL3426309
 10.1 Ki —
No preferred name
CHEMBL5751446
 10.1 IC50 —

Approved Drugs

Structure Compound First Approval
RITLECITINIB
CHEMBL4085457
 2023
ZANUBRUTINIB
CHEMBL3936761
 2019
FEDRATINIB
CHEMBL1287853
 2019
NINTEDANIB
CHEMBL502835
 2014
IBRUTINIB
CHEMBL1873475
 2013
SUNITINIB
CHEMBL535
 2006
DASATINIB
CHEMBL5416410
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T04:40:53Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2959